The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In the biotech sector, a single insurer decision can reshape a startup's trajectory. According to reports, ARS Pharmaceuticals stock collapsed after CVS Caremark declined to add its epinephrine spray Neffy to its formulary, delaying the final decision to January. This refusal marks a major setback for a company that relies on formulary inclusion by major pharmacies to generate revenue.
Formulary inclusion by CVS Caremark is critical for a drug's commercial success, as the company covers millions of beneficiaries in the United States. This development follows Neffy's FDA approval as the first nasal epinephrine spray for anaphylaxis, positioning it as a promising entrant in the emergency allergy market. Its exclusion from CVS's list severely limits patient access.
Sign in to access this content
Sign InInvestors are now watching for any revision of CVS's decision or potential agreements with other pharmacies. The market will also monitor early quarterly sales data to gauge the financial impact of this exclusion. With no other approved products in ARS Pharma's pipeline, the company's future hinges on formulary decisions.